Flag of the European Union EU Clinical Trials Register Help

Clinical trials for adhd

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    147 result(s) found for: adhd. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2015-004271-78 Sponsor Protocol Number: CIAOII Start Date*: 2016-05-31
    Sponsor Name:King's College London
    Full Title: Randomised controlled trial of the short term effects of OROS-methylphenidate on ADHD symptoms and behavioural outcomes in young male prisoners with attention deficit hyperactivity disorder
    Medical condition: Attention Deficit Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10064104 ADHD LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-005330-12 Sponsor Protocol Number: RAA06-003 Start Date*: 2006-05-11
    Sponsor Name:King's College London (IOP)
    Full Title: Omega-3 Fatty Acids Supplementation for Adolescent Boys with Attention Deficit Hyperactivity Disorder : a double-blind, randomized controlled trial
    Medical condition: Attention deficit / hyperactivity disorder (ADHD) is defined by DSM-IV criteria, which shows inattention, hyperactivity and impulsivity. ADHD is one of the most common child psychiatric disorders,...
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-005017-12 Sponsor Protocol Number: EyeADHD-01 Start Date*: 2014-03-31
    Sponsor Name:Parnassia Bavo Groep - PsyQ
    Full Title: Looking into the eye of ADHD. Investigating the relationship between ADHD, the delayed circadian rhythm and the functioning of the eye.
    Medical condition: Adults with ADHD and suboptimal eye functioning.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004873 10064104 ADHD LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-000492-17 Sponsor Protocol Number: NL39440.029.10 Start Date*: 2012-10-29
    Sponsor Name:Afdeling Klinische Neuropsychologie Vrije Universiteit Amsterdam
    Full Title: The Effects of Long-acting Methylphenidate on Academic Activity and Related Constructs in Children with ADHD: A Randomised Placebo Controlled Trial
    Medical condition: Attention-deficit hyperactivity disorder (ADHD)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000191-24 Sponsor Protocol Number: B4Z-UT-LYEL Start Date*: 2008-05-09
    Sponsor Name:Eli Lilly Nederland
    Full Title: An Open Label Pilot Study of Atomoxetine Hydrochloride in Adolescents with Attentioin-Deficit/Hyperactivity Disorder and Comorbid Cannabis Abuse
    Medical condition: Attention Deficit Hyperactivity Disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003736 Attention deficit/hyperactivity disorder LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000517-37 Sponsor Protocol Number: CIAOProject Start Date*: 2012-11-08
    Sponsor Name:King's College London [...]
    1. King's College London
    2. South London and Maudsley NHS Foundation Trust
    Full Title: A pilot study of Concerta XL in adult offenders with ADHD
    Medical condition: Attention deficit hyperactivity disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10064104 ADHD LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-019981-94 Sponsor Protocol Number: ADOP Start Date*: 2010-09-21
    Sponsor Name:HUS/ Neuropsykiatrian poliklinikka
    Full Title: Attention Deficit Hyperactivity Disorder (ADHD) and opioid maintenance therapy. A randomized, placebo-controlled study of the efficacy of atomoxetine for treating adult ADHD in patients receiving o...
    Medical condition: Patients will be recruited from out-patient clinics treating opioid dependent patients with buprenorphine or methadone maintenance therapy. Patients will be screened for ADHD symptoms. Based on the...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064104 ADHD LLT
    Population Age: Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-000419-98 Sponsor Protocol Number: B4Z-US-LYEI Start Date*: 2021-12-13
    Sponsor Name:Eli Lilly and Company
    Full Title: Neurophysiology of Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Dyslexia: Functional Magnetic Resonance Imaging (fMRI) Measures of Brain Activation During Attention and Reading Tas...
    Medical condition: Attention Deficit Hyperactivity Disorder, Dyslexia.
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004873 10003735 Attention deficit-hyperactivity disorder LLT
    20.0 10029205 - Nervous system disorders 10013932 Dyslexia PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-000210-19 Sponsor Protocol Number: CRIT124D2302E1 Start Date*: 2011-06-10
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 6-month, open-label extension to a 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-on...
    Medical condition: Adult patients with childhood-onset Attention Deficit Hyperactivity Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10003735 Attention deficit-hyperactivity disorder LLT
    14.0 10037175 - Psychiatric disorders 10003737 Attention deficit/hyperactivity disorder NOS LLT
    14.0 10037175 - Psychiatric disorders 10003736 Attention deficit/hyperactivity disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) BE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-002897-31 Sponsor Protocol Number: 1453 Start Date*: 2006-04-04
    Sponsor Name:North Bristol NHS Trust
    Full Title: Objective assessment of attention difficulties in adults with Attention-Deficit Hyperactivity Disorder (ADHD)
    Medical condition: Attention-Deficit Hyperactivity Disorder (ADHD) in Adults
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-021533-31 Sponsor Protocol Number: CRIT124D2302 Start Date*: 2011-02-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD
    Medical condition: Adult patients with childhood-onset Attention Deficit Hyperactivity Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10003735 Attention deficit-hyperactivity disorder LLT
    14.1 10037175 - Psychiatric disorders 10003737 Attention deficit/hyperactivity disorder NOS LLT
    14.1 10037175 - Psychiatric disorders 10003736 Attention deficit/hyperactivity disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) BE (Completed) DK (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2009-018161-12 Sponsor Protocol Number: SPD503-315 Start Date*: 2010-12-23
    Sponsor Name:Shire Development Inc
    Full Title: A Phase 3, Double-blind, Placebo-controlled, Multicentre, Randomised withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adol...
    Medical condition: Attention-Deficit/Hyperactive Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10068451 ADHD, combined type LLT
    14.1 100000004873 10068453 ADHD, predominantly inattentive type LLT
    14.1 100000004873 10068452 ADHD, predominantly hyperactive-impulsive type LLT
    14.1 100000004873 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) ES (Completed) SE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002221-21 Sponsor Protocol Number: SPD503-312 Start Date*: 2011-08-30
    Sponsor Name:Shire Development Inc
    Full Title: A Phase 3, Double-blind, Randomized, Multi-center, Placebo controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once daily Dosing with Extended-release Guanfacin...
    Medical condition: Attention-Deficit/Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10068451 ADHD, combined type LLT
    14.0 10037175 - Psychiatric disorders 10068453 ADHD, predominantly inattentive type LLT
    14.0 10037175 - Psychiatric disorders 10068452 ADHD, predominantly hyperactive-impulsive type LLT
    14.0 10037175 - Psychiatric disorders 10064104 ADHD LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-001866-18 Sponsor Protocol Number: B4Z-MC-LYCK Start Date*: 2021-12-02
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Crossover Comparison of Atomoxetine and Placebo in Child Outpatients With Attention-Deficit/Hyperactivity Disorder, Reading Disorder, or Comorbid Attention-Deficit/Hyper...
    Medical condition: Attention-Deficit/Hyperactivity Disorder (AD/HD)
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004873 10003735 Attention deficit-hyperactivity disorder LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-012261-61 Sponsor Protocol Number: 2009-4-CC Start Date*: 2009-08-20
    Sponsor Name:Academic Medical Center
    Full Title: Why methylphenidate is not successful in cocaine-dependent ADHD patients: a SPECT study comparing DAT before and after methylphenidate treatment in ADHD patients with and without cocaine dependence
    Medical condition: ADHD with and without substance use disorder (SUD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064104 ADHD LLT
    9.1 10009815 Cocaine addiction LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005701-32 Sponsor Protocol Number: B4Z-IT-LYDS Start Date*: 2006-03-07
    Sponsor Name:ELI LILLY
    Full Title: An Open-Label Study of the Efficacy of Atomoxetine Hydrochloride on Quality of Life of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder with or without comorbid conditions
    Medical condition: Child or adolescent patients with Attention-Deficit/ Hyperactivity Disorder ADHD
    Disease: Version SOC Term Classification Code Term Level
    6.1 10003736 PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-003285-26 Sponsor Protocol Number: ASTA Start Date*: Information not available in EudraCT
    Sponsor Name:Universität Mainz, Klinik und Poliklinik für Kinder- und Jugendpsychiatrie und -psychotherapie
    Full Title: Effect of methylphenidate formulation on ADHD-patients' adherence to medical treatment. A comparison of Medikinet retard® (ER) once daily and Medikinet® (IR) twice daily in children and adolescents...
    Medical condition: Effect of methylphenidate formulation on ADHD-patients adherence to treatment
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000320-18 Sponsor Protocol Number: FASE01 Start Date*: 2012-11-22
    Sponsor Name:Parnassia Bavo Groep - PsyQ
    Full Title: Phase shift in adult ADHD of sleep and apetite.
    Medical condition: Delayed Sleep Phase Syndrome (DSPS) in adult patients with Attention-Deficit/Hyperctivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004873 10064104 ADHD LLT
    16.1 10029205 - Nervous system disorders 10012209 Delayed sleep phase PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-000685-29 Sponsor Protocol Number: B4Z-KL-LYEC Start Date*: 2021-08-05
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3b, Randomized, Open-Label Assessment of Response to Various Doses of Atomoxetine Hydrochloride in Korean Pediatric Outpatients With Attention-Deficit/Hyperactivity Disorder
    Medical condition: Attention-Deficit/Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004873 10003735 Attention deficit-hyperactivity disorder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-003888-59 Sponsor Protocol Number: C.2524.0493.01 Start Date*: 2014-03-17
    Sponsor Name:University of Amsterdam
    Full Title: ADHD: Medication or Meditation?
    Medical condition: Attention Deficit Hyperactivity Disorder (ADHD)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 05:45:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA